MARY BREWER: Open Payments
NPI 1255943932 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$540 in 29 payments from 15 companies in 2025. Trend: 2023 $798 · 2024 $639 · 2025 $540
Food & beverage: $540
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $127 |
| ABBVIE INC. | 4 | $83 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| TOLMAR, INC. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
Products named: FARXIGA, TRELEGY ELLIPTA, BREZTRI, VRAYLAR, JATENZO, NEXLETOL, MOUNJARO, Auvelity.
Industry payments across MS — which companies pay providers there.
